SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA
Open Access
- 9 August 2019
- journal article
- correction
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 35 (10), 1825
- https://doi.org/10.1093/ndt/gfz137
Abstract
SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA, Nephrology Dialysis Transplantation 2019; gfy407. doi: 10.1093/ndt/gfy407This publication has 1 reference indexed in Scilit: